Identifying Molecular or Cellular Level Pathomechanisms for Possible Therapeutic/Neuroprotective Interventions in Traumatic Brain Injury
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 1087
Special Issue Editors
2. Department of Neurosurgery, Medical School, University of Pecs, 7623 Pecs, Hungary
Interests: traumatic brain injury (head injury): biomarkers; animal models; repetitive mild TBI; coagulopathy
2. Neurotrauma Research Group, Szentagothai Research Centre, University of Pecs, H-7624 Pecs, Hungary
3. ELKH-PTE Clinical Neuroscience MR Research Group, H-7623 Pecs, Hungary
Interests: traumatic brain injury (head injury); biomarkers; animal models; histopathological consequences; repetitive mild TBI; therapeutic (neuroprotective) interventions
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
It is well known that traumatic brain injury represents a common clinical condition with a huge socio-economic burden. While, according to the data recently published by the Global Burden of Disease Study collaborators, there are more than 27 million new TBI cases estimated yearly worldwide associated with more than 8 million years of life lived with disability, other studies presume almost 70 thousand lethal cases in the USA and 75 thousand deaths, on top of about one million hospitalizations in Europe yearly, and all these numbers are still increasing.
Although the above-described data confirm the clear clinical need for causal (cellular level/neuroprotective) and, preferably, individualized therapeutic interventions—mainly due to the hypercomplex nature of possible pathological/pathophysiological sequelae induced by the head injury—so far (despite some clinical trials with controversial results with hypothermia, cyclosporine A and some steroid hormone analogues), there have been no real breakthroughs in this important field.
In light of the above, our current Special Issue is open to any clinical or experimental data related to any kind of promising neuroprotective interventions and/or revealed pathological alterations or pathophysiological processes which could serve as potential therapeutic targets in the near future.
Dr. Krisztina Amrein
Dr. Endre Czeiter
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- traumatic brain injury
- head injury
- clinical study
- experimental model
- neuroprotective intervention
- therapy
- pathomechanism
- molecular
- cellular
